





Introduction to NGS

DR. SEBASTIAAN THEUNS, DVM CEO & CO-FOUNDER

WEBINAR FOR THE DEVELOPING COUNTRIES VACCINE MANUFACTURERS NETWORK 20-07-2022


Disclaimer

This presentation is intended to give a **global overview of the next generation sequencing landscape**. The speaker made use of publicly available data is not responsible for the accuracy of these data.

The presentation is **not intended to give advice or recommendations** for the use of certain **technologies or brands**.

Sebastiaan Theuns is **co-founder and co-owner of PathoSense**, **a Ghent University spin-off company** that makes commercial use of Oxford Nanopore Technologies for diagnostics of veterinary infectious diseases.

Sequencing: the analysis of the genetic code



Next-generation sequencing technologies

illumina

iontorrent by Thermo Fisher Scientific E Element Biosciences












VG ULTIMA GENOMICS

> <u>Strong competition</u>: market - technology - accuracy - output - read length

Read-length and genome assembly

Short read



















Long read





Read-length and genome assembly

Short read










ULTIMA GENOMICS








Long read







Illumina - sequencing by synthesis



illumina

Illumina sequencing devices



Parameter/device	iSeq 100	MiSeq	NextSeq2000	HiSeq	NovaSeq
Max output	1.2 GB	15GB	360GB	1.5 TB	6 TB
Max # reads	4 million	25 million	2.4 billion	5 billion	20 billion
Max read length	2x150bp	2x300bp	2x150 bp	2x150bp	2x250bp
Accuracy	>80% of bases Q30	>70% of bases Q30	>85% of bases Q30	>75% of bases Q30	>75% of bases Q30
Max seq. time	17.5h	56h	48h	3.5 days	~44h
Investment	~\$20K		~ \$300K		~\$1M





MGI: DNB Seq technology


- Circularisation of DNA & Rolling Circle Amplification
- Sequencing of DNA Nanoballs (DNB)
- BGI Republic of China
- Entry in EU market in 2022





DNBSeq-G50 150 GB

DNBSeq-T7 6 TB





IonTorrent

iontorrentThermoFisherby Thermo Fisher ScientificS C I E N T I F I C

- Ion semiconductor, well established in the market
- Short-read platform: 200 600 bp
- Output per flowcell: 0.3 to 25 GB
- Seq duration: 3 21.5 h
- High sequencing quality
- Up to two flowcells



Some (short-read) technologies to follow





ULTIMA GENOMICS


No flowcells, new chemistry

US: San Diego



Read-length and genome assembly

Short read










by Thermo Fisher Scientific





ULTIMA GENOMICS


Long read








Pacific Biosciences (PacBio)











1. Light from below (wavelength to large, cannot pass through the waveguide) 2. Attenuated light from excited fluorophores can penetrate through the ZMW

3. DNA & polymerase complexed is present in the ZMW
> Incorporation of phospo-linked nucleotides containing a fluorophore 4. Attenuated light is >1000 stronger than light



Single-moleculare real-time sequencing (SMRT)

Pacific Biosciences (PacBio)



HiFi Reads Other CCS Reads

Q40


≥Q50

Sequel II

Max 8 million reads Max 30h seq per cell 150 GB



Hifi Sequencing



HIFI READ LENGTH (BP)

Oxford Nanopore Technologies










Nanopore sequencing devices




Parameter/device	Flongle	MinION	GridION X5	PromethION	PromethION
			Ghuion X5	2	24 or 48
Max output	2.8 GB	30GB	150GBP	0.5 TB	7 to 14 TB
Channels	~ 100	512	5 x 512	3000	24 or 48 x 3000
Read length	<		Short to ultralong (4MB)		>
Accuracy	<		≥≤	A STORE	
Seq time	<		I munu in munu	I mummer to	annun annun



Problem of classic pathogen/adv. agent testing



Challenges of ad-random sequencing of pathogens












Spin-off of Ghent University

° Oct 2020 Co-founders Dr. Theuns & Prof. Nauwynck







No selection, scalable to all species

Future perspectives

- NGS is an **innovative field** in continous evolution
- Advances in technologies > **challenges** for regulatory bodies
- NGS is available as a diagnostic tool for pathogens in veterinary medicine
- NGS has value in R&D and manufacturing of biologicals
 - Lead selection rapid mutation ID
 - Screening for adventitious agents from early passages till production
 - Pharmacovigilance: rapid detection of mutations, recombination, reassortments...





Developing Countries Vaccine Manufacturers Network





UGhent Industrial Research Fund





Thank you